
Anti-scar RNA patch maker says it can expand technology to tackle eczema, hyperpigmentation, wrinkles
- co11ab
-
biotech, medtech, skincare, keloidscar, hypertrophicscar
- 21 October 2024
RNAscence Biotechnology says its RNA patch technology can broaden its impact beyond scar treatment to tackle a variety of skin issues from eczema to hyperpigmentation and wrinkles.

Starting a start-up: Medtech start-up moulding the future of orthopaedic care through 4D printing
- co11ab
-
customisablecasts, medtech, healthtech, 4Dprinting
- 24 September 2024
Entrepreneur Abel Teo, 29, from Castomize - a start-up making orthopedic devices using 4D-printing technology

Emerging Trends in Biomedical and Health Sciences
- co11ab
-
technologies, trends, biotech, medtech, digitalhealth, investment, invest
- 14 August 2024
Investment landscape report and next generation of healthcare technologies.

“Coffee with X” Series – legal consultation by fsLAW
- co11ab
-
legal, consultation, coffeewithX
- 29 July 2024
Legal consultation to address startups' needs.

Medtech bench testing and regulatory strategies
- co11ab
-
regulatory, qms, quality management system, medtech
- 24 July 2024
Build rapport with regulators to ensure smoother process of document submissions.

Intranasal splint approval by Health Science Authority
- co11ab
-
biotech, medtech, HSAapproval, biomaterials, biopolymers, IntranasalSplint
- 31 May 2024
Intranasal Splint Approval by HSA.

VC investment agreements for biomedtech entrepreneurs
- co11ab
-
equity, biotech, medtech, digitalhealth, investment, founders, contracts, agreements
- 16 May 2024
Demystifying the complexities of VC investment agreements.

Nucleate Ignite Series – Educational series aimed to convey in-depth technical understanding of crucial roles in the biotech world
- co11ab
-
productdevelopment, regulatory, biotech, IP, drugdiscovery, Biotherapeutics
- 22 February 2024
The processes involved in creating a therapeutic program in biotech and pharma companies, and how it differs from academic science.

Cantabio Pharmaceuticals awarded grant from the Michael J. Fox Foundation to develop novel DJ-1 protein replacement therapy for the treatment of PD
- co11ab
-
drugdiscovery, cantabio, PD, parkinson, biotech
- 07 February 2024
Grant enables further development of Cantabio's innovative DJ-1 replacement therapy for the treatment of Parkinson's disease